Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

News

  • Home
  •  
  • News



  • Most Read
  • Latest Comments
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • News

    Smart pain assessment app now used by more than half of Australia’s residential aged care providers
    Public
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • News

    Fledgling fintech hopes millennials put their Douugh into micro-investing ‘super’ app
    Public
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    • News

    🎵 The knee bone’s connected to the… collagen rope device (?!)
    Public
  • Why one contentious FDA drug approval is good news for Actinogen Medical
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial
    • Review
    • September 1, 2022

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    • News

  • As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    • News

  • Can a sleep disorder signal depression? Medibio study says yes
    Can a sleep disorder signal depression? Medibio study says yes
    • News

  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

  • Medibio advances to FDA application for mental health screening software
    • News

    Medibio advances to FDA application for mental health screening software

    Mental health medtech company Medibio (ASX: MEB) has continued its accelerated plans towards FDA approvals under new management with the company having lodged an FDA application overnight for their mental health screening software – MEBsleep.  Having collected the required clinical data MEBsleep (previously named STAGER) tested more than 1,000 individuals using Medibio’s sleep staging algorithm

    Read More
    Public
  • KNeoMedia secures Indian distributor for EduTech platform targeting 100m student
    • News

    KNeoMedia secures Indian distributor for EduTech platform targeting 100m student

    Education tech company KNeoMedia (ASX: KNM) is set to increase its global reach to the 1.5 million schools in India via an exclusive licensing agreement with Indian-based firm Augustya.  The agreement will give Augustya exclusive rights to market and sell KneoWorld technology in India with KNeoMedia to receive approximately $40 for each seat licence sold. 

    Read More
    Public
  • LiveHire shares surge 59% after winning major $1.2m North America HR contract
    • News

    LiveHire shares surge 59% after winning major $1.2m North America HR contract

    Employment tech company LiveHire (ASX: LVH) has made a significant foray into the North American market having won the prized contract from Ian Martin Group which will implement the LiveHire human resources platform in the United States and Canada.  The Direct Sourcing contract is expected to deliver LiveHire $1.2 million over 3 years with an

    Read More
    Public
  • Fourth time lucky, Mustera secures approval for lavish Perth apartment complex
    • News

    Fourth time lucky, Mustera secures approval for lavish Perth apartment complex

    Having endured a rocky road over the past 12 months where their major project was rejected by the regulatory board three times, property developer Mustera Property Group (ASX: MPX) is finally set to get their Forbes project underway having received approval from the Joint Development Assessment Panel (JDAP). The $65m ‘Forbes Residences’ project located in

    Read More
    Public
  • Novatti payment processing revenue up 67% as COVID-19 sends world cashless
    • News

    Novatti payment processing revenue up 67% as COVID-19 sends world cashless

    Australian fintech company Novatti Group (ASX: NOV) has reported a 67% rise in revenues from their payments processing business, a record for the company which has seen heightened activity amidst coronavirus lockdowns as businesses turn to digital payment solutions.  For the quarter ending 31 March 2020, Novatti’s $1.72 million (unaudited) in payment processing revenue represented

    Read More
    Public
  • Botanix up 91% after FDA grants QIPD status to advance antimicrobial products
    • News

    Botanix up 91% after FDA grants QIPD status to advance antimicrobial products

    Cannabinoid company Botanix Pharmaceuticals (ASX: BOT) has found its way into the fast lane towards FDA approval for their antimicrobial product BTX 1801, developed to prevent post-surgical infections, having secured Qualified Infectious Disease Product (QIPD) designation which will expedite their FDA review process. The designation of QIPD status for BTC 1801 is the first for

    Read More
    Public
  • ClearVue to commence solar product trials in lucrative China market
    • News

    ClearVue to commence solar product trials in lucrative China market

    Environmental tech company ClearVue Technologies (ASX: CPV) is poised for a launch into the lucrative Mainland China market having entered an agreement with China Jinmao to trial ClearVue’s solar technology with a view towards exclusive distribution.  The trial project will be undertaken by China Jinmao’s wholly owned subsidiary Jinmao Green Building which will apply ClearVue’sRead More
    Public
  • With 400 million glove backlog, VIP Gloves sold out till December 2020
    • News

    With 400 million glove backlog, VIP Gloves sold out till December 2020

    Shares in the lightly traded gloves manufacturer VIP Gloves (ASX: VIP) have skyrocketed this morning on news that the Company has such a large backlog of orders that their 24/7 production capacity is fully committed until December 2020.  With their production facilities based in Malaysia and not impacted by the Malaysian Government’s COVID-19 biosecurity measures,

    Read More
    Public
  • Osteopore continues winning streak with bone regeneration product approvals
    • News

    Osteopore continues winning streak with bone regeneration product approvals

    3D printing medtech company Osteopore (ASX: OSX) is set to continue their successful streak, following news that the company has received Australian Therapeutics Goods Administration (TGA) approval for three craniofacial products, after being placed into a trading halt Friday afternoon. The Osteomesh, Osteoplug, and Osteoplug-C, are used primarily to fill voids in a patient’s bone,

    Read More
    Public
  • RooLife shares surge 300% on appointment as marketing partner for Alipay
    • News

    RooLife shares surge 300% on appointment as marketing partner for Alipay

    With more than 1.2 million users, Chinese online payment platform Alipay has appointed Australian eCommerce firm RooLife Group (ASX: RLG) as an Alipay Marketing Partner, sending the small cap company’s stock up 300% in morning trade.  The Marketing Cooperation Agreement will see Roolife provide business services that enable them to list, promote and sell products

    Read More
    Public
  • «
  • ‹
  • 293
  • 294
  • 295
  • 296
  • 297
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.